Form 4: Gossamer Bio Director Acquires 115,000 Stock Options

Director Russell J. Cox acquired 115,000 non-qualified stock options in Gossamer Bio, Inc. on June 6, 2024, as part of the Non-Employee Director Compensation Program.

Summary

• On June 6, 2024, Russell J. Cox, a director of Gossamer Bio, Inc., acquired 115,000 non-qualified stock options.
• The options were granted as part of the Non-Employee Director Compensation Program.
• The exercise price of the options is $0.60.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service on the board.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to director compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. It is a neutral event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies. The granting of stock options is a typical way to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, are common across the biotechnology industry to incentivize performance and align interests with shareholders.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation programs.
• The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates